Protagonist Therapeutics (PTGX) Competitors

Protagonist Therapeutics (NASDAQ:PTGX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.

Which has more volatility & risk, PTGX or VTRS?

Protagonist Therapeutics has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500. Comparatively, Viatris has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Do analysts prefer PTGX or VTRS?

Protagonist Therapeutics currently has a consensus price target of $62.56, indicating a potential upside of 26.22%. Viatris has a consensus price target of $10.50, indicating a potential upside of 17.19%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Viatris	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Which has stronger valuation and earnings, PTGX or VTRS?

Viatris has higher revenue and earnings than Protagonist Therapeutics. Viatris is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$434.43M	7.00	-$78.96M	$4.20	11.80
Viatris	$14.74B	0.73	$54.70M	-$0.53	-16.91

Do insiders & institutionals have more ownership in PTGX or VTRS?

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 5.4% of Protagonist Therapeutics shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor PTGX or VTRS?

Protagonist Therapeutics received 266 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 61.49% of users gave Protagonist Therapeutics an outperform vote while only 34.85% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
Protagonist Therapeutics	Outperform Votes 289 61.49%	Underperform Votes 181 38.51%
Viatris	Outperform Votes 23 34.85%	Underperform Votes 43 65.15%

Is PTGX or VTRS more profitable?

Protagonist Therapeutics has a net margin of 52.76% compared to Viatris' net margin of -5.87%. Protagonist Therapeutics' return on equity of 34.68% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	52.76%	34.68%	30.98%
Viatris	-5.87%	16.46%	7.09%

Does the media favor PTGX or VTRS?

In the previous week, Viatris had 9 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 15 mentions for Viatris and 6 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.24 beat Viatris' score of 0.02 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Protagonist Therapeutics beats Viatris on 16 of the 19 factors compared between the two stocks.